Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women

被引：10

作者：

Vogelvang, TE

Mijatovic, V

Kenemans, P

Schalkwijk, CG

van der Mooren, MJ

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynecol, ICaR, NL-1007 MB Amsterdam, Netherlands

[2] Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, ICaR, NL-1007 MB Amsterdam, Netherlands

[3] Vrije Univ Amsterdam, Med Ctr, Project Aging Women, NL-1007 MB Amsterdam, Netherlands

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 09期

关键词：

D O I：

10.1016/j.amjcard.2004.07.099

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We investigated the 12-week effects of 3 doses of HMR 3339, a novel selective estrogen receptor modulator, in comparison with raloxifene and placebo, on plasma concentrations of C-reactive protein in 96 healthy postmenopausal women. A dose-dependent reduction in C-reactive protein was observed, the largest reduction with HMR 3339 50 mg. (C) 2004 by Excerpta Medica, Inc.

引用

页码：1205 / 1208

页数：4

共 50 条

[31] The new selective estrogen receptor modulator HMR 3339 prevents ovariectomy-induced bone loss and alteration of bone strength in adult rats.
Ammann, P
Bourrin, S
Brunner, F
Gaillard, M
Meyer, JM
Rizzoli, R
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S481 - S481
[32] The decrease in bone mineral mass and in bone strength induced by ovariectomy in adult rats is corrected by the new selective estrogen receptor modulator HMR 3339.
Ammann, P
Brunner, F
Gaillard, M
Meyer, JM
Rizzoli, R
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S481 - S481
[33] C-reactive protein as a predictor of cardiovascular risk in postmenopausal women
Abomandor, Hala G.
Al-Daydamony, Mohammad M.
Shehata, Mohammad
EUROPEAN HEART JOURNAL SUPPLEMENTS, 2016, 18 (0H) : H9 - H9
[34] Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women
Schultze-Mosgau, Marcus-Hillert
Schuett, Barbara
Hafner, Frank-Thorsten
Zollmann, Frank
Kaiser, Andreas
Hoechel, Joachim
Rohde, Beate
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 16 - 24
[35] Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women
Vongpatanasin, W
Tuncel, M
Wang, ZY
Arbique, D
Mehrad, B
Jialal, I
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (08) : 1358 - 1363
[36] Addition of statin attenuates the increase in C-reactive protein during estrogen replacement therapy in postmenopausal women
Koh, EK
Osako, G
Schenke, W
Cannon, RO
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) : 238A - 238A
[37] The Effects of Raloxifene on Serum Lipid Profiles, C-Reactive Protein and Homocysteine Levels in Postmenopausal Women
Turan, Gulizar Arzu
Dogan, Erbil
Posaci, Cemal
Caliskan, Sezer
Guclu, Serkan
Altunyurt, Sabahattin
JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, 2006, 7 (02) : 125 - 129
[38] Effects of raloxifene and hormone replacement therapy on homocysteine and C-reactive protein levels in postmenopausal women
Paul, S
Dean, RA
Tracy, RP
Cox, DA
Walsh, BW
Anderson, PW
CIRCULATION, 1998, 98 (17) : 7 - 8
[39] Lack of association of plasma C-reactive protein with leptin levels in healthy premenopausal women
Jae, SY
Park, KH
Eum, HJ
Yoon, SH
Park, WH
Mercedes, C
OBESITY RESEARCH, 2004, 12 : A158 - A158
[40] High Levels of C-Reactive Protein Are Positively Associated with Isolated Postchallenge Hyperglycemia in Postmenopausal Women
Hwu, Chii-Min
Lin, Yi-Chun
Lin, Ming-Wei
METABOLIC SYNDROME AND RELATED DISORDERS, 2016, 14 (07) : 334 - 339

← 1 2 3 4 5 →